| Market Cap | 54.11M | P/E | - | EPS this Y | 55.70% | Ern Qtrly Grth | - |
| Income | -14.26M | Forward P/E | -4.70 | EPS next Y | 25.70% | 50D Avg Chg | -26.00% |
| Sales | 23.68M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
| Dividend | N/A | Price/Book | 0.94 | EPS next 5Y | - | 52W High Chg | -67.00% |
| Recommedations | 2.00 | Quick Ratio | 1.18 | Shares Outstanding | 26.32M | 52W Low Chg | - |
| Insider Own | 13.59% | ROA | -10.99% | Shares Float | 22.79M | Beta | 0.33 |
| Inst Own | 6.73% | ROE | -25.72% | Shares Shorted/Prior | 339.99K/440.71K | Price | 2.16 |
| Gross Margin | 51.88% | Profit Margin | -60.22% | Avg. Volume | 83,419 | Target Price | 7.01 |
| Oper. Margin | -53.69% | Earnings Date | Jul 5 | Volume | 52,444 | Change | -7.49% |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.
